Αποτελέσματα Αναζήτησης
28 Αυγ 2024 · mRNA-1608 vaccine candidate is under development for the prevention of Herpes simplex virus (HSV-2) Infections such as genital herpes. The vaccine candidate is an mRNA vaccine developed based on mRNA technology platform. It is administered through intramuscular route.
5 Μαρ 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States.
21 Δεκ 2022 · BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine...
4 Απρ 2024 · To address this shortcoming, the U.S. government issued a Notice of Special Interest (NOSI) NOT-AI-24-028 on March 27, 2024, intending to stimulate additional focus on developing diagnostics, therapeutics, and vaccines targeting HSV.
13 Μαΐ 2024 · Fred Hutch virologists eliminated at least 90% of HSV-1 in preclinical models of oral and genital herpes and reduced viral shedding in a study published in Nature Communications.
21 Δεκ 2022 · First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic.
8 Ιαν 2023 · BNT163 is not the only herpes vaccine candidate conducting early-stage research. Still, it is the only mRNA vaccine that encodes three HSV-2 glycoproteins to help to prevent HSV cellular entry and spread, as well as counteract the immunosuppressive properties of HSVs.
